PB2095: ELOTUZUMAB OR DARATUMUMAB IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE (EPD AND DPD) IN RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM): A NETWORK META-ANALYSIS

• Tassia Cristina Decimoni,
• Adriana Cury,
• James Farrell,
• Nicolas Bertin,
• Claire Fischer,
• Victor Genestier,
• Jorge Vaz Pinto Neto,
• Glaciano Ribeiro,
• Angelo Maiolino

Affiliations

Tassia Cristina Decimoni

1 Bristol Myers Squibb, São Paulo, Brazil

Adriana Cury

1 Bristol Myers Squibb, São Paulo, Brazil

James Farrell

2 Bristol Myers Squibb, Dublin, Ireland

Nicolas Bertin

3 Amaris, Health Economics and Market Access, London, England, United Kingdom

Claire Fischer

4 Amaris, Health Economics and Market Access, Montreal, Canada

Victor Genestier

5 Amaris, Health Economics and Market Access, Toronto, Canada

Jorge Vaz Pinto Neto

6 Cettro, Centro de Câncer de Brasília, DF, Brazil

Glaciano Ribeiro

7 Hospital das Clínicas da Universidade Federal de Minas Gerais, MG, Brazil

Angelo Maiolino

8 Universidade Federal do Rio de Janeiro, RJ, Brazil